Intraocular properties of an alkoxyalkyl derivative of cyclic 9-(S)-(3-hydroxyl-2-phosphonomehoxypropyl) adenine, an intravitreally injectable anti-HCMV drug in rabbit and guinea pig

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 5, 2007, Pages 433-444

  Tammewar, Ajay M ^a   Cheng, Lingyun ^a   Hostetler, Karl Y ^b   Falkenstein, Iryna ^a   Beadle, James R ^b   Barron, Erin C ^a   Kozak, Igor ^a   Freeman, William R ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ANTIVIRUS AGENT; CIDOFOVIR; CYCLIC CIDOFOVIR; GANCICLOVIR; HEXADECYLOXYPROPY L9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; HEXADECYLOXYPROPYL CIDOFOVIR; HEXADECYLOXYPROPYL CYCLIC 9(3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; HEXADECYLOXYPROPYL CYCLIC CIDOFOVIR; HEXADECYLOXYPROPYL GANCICLOVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG RELEASE; ELECTRORETINOGRAPHY; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; NONHUMAN; OPHTHALMOSCOPY; SLIT LAMP; VITREOUS BODY;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; DELAYED-ACTION PREPARATIONS; ELECTRORETINOGRAPHY; EYE; FIBROBLASTS; GUINEA PIGS; INJECTIONS; INTRAOCULAR PRESSURE; ORGANOPHOSPHORUS COMPOUNDS; RABBITS; VITREOUS BODY;

EID: 36749054114     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0018     Document Type: Article

References (36)

1. Jabs, D.A., and Bartlett, J.G. AIDS and ophthalmology: A period of transition. Am. J. Ophthalmol. 124(2):227-233, 1997.
2. Jacobson, M.A., Stanley, H., Holtzer, C., et al. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30(1):231-233, 2000.
3. Jabs, D.A., Van Natta, M.L., Thorne, J.E., et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology 111(12):2224-2231, 2004.
4. Jabs, D.A. Ocular manifestations of HIV infection. Trans. Am. Ophthalmol. Soc. 93:623-683, 1995.
5. Jabs, D.A., Van Natta, M.L., Kempen, J.H., et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am. J. Ophthalmol. 133(1):48-61, 2002.
6. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology 101(7):1250-1261, 1994.
7. Smith, I.L., Flores-Aguilar, M., Taskintuna, I., et al. Cytomegalovirus resistance is associated with clinical failure in AIDS patients receiving ganciclovir treatment for retinitis. The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 15-18, 1996, New Orleans, LA.
8. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Ann. Intern. Med. 126(4):264-274, 1997.
9. Smith, I.L., Cherrington, J.M., Jiles, R.E., et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176(1):69-77, 1997.
10. Spector, S.A., Weingeist, T., Pollard, R.B., et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. The AIDS Clinical Trials Group and the Cytomegalovirus Cooperative Study Group. J. Infect. Dis. 168(3):557-563, 1993.
11. Studies of Ocular Complications of the AIDS Research Group, in Collaboration with the AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch. Intern. Med. 155(1):65-74, 1995.
12. Studies of Ocular Complications of the AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch. Ophthalmol. 114(1):23-33, 1996.
13. Martin, D.F., Parks, D.J., Mellow, S.D., et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch. Ophthalmol. 112(12):1531-1539, 1994.
14. Dunn, J.P., Van Natta, M., Foster, G., et al. Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Retina 24(1):41-50, 2004.
15. Kuppermann, B.D., Quiceno, J.I., Flores-Aguilar, M., et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J. Infect. Dis. 168(6):1506-1509, 1993.
16. Rahhal, F.M., Arevalo, J.F., Munguia, D., et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 103(7):1078-1083, 1996.
17. Jager, R.D., Aiello, L.P., Patel, S.C., et al. Risks of intravitreous injection: A comprehensive review. Retina 24(5):676-698, 2004.
18. Chavez-de la Paz, E., Arevalo, J.F., Kirsch, L.S., et al. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis: Analysis and prevention. Ophthalmology 104(3):539-544, 1997.
19. Banker, A.S., Arevalo, J.F., Munguia, D., et al. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am. J. Ophthalmol. 124(2):168-180, 1997.
20. Cundy, K.C., Lynch, G., Shaw, J.P., et al. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Curr. Eye Res. 15(5):569-576, 1996.
21. Cheng, L., Hostetler, K.Y., Chaidhawangul, S., et al. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir. Invest. Ophthalmol. Vis. Sci. 43(2):515-521, 2002.
22. Cheng, L., Hostetler, K.Y., Lee, J., et al. Characterization of a novel intraocular drug delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest. Ophthalmol. Vis. Sci. 45(11):4138-4144, 2004.
23. Lu, S., Cheng, L., Hostetler, K.Y., et al. Intraocular properties of hexadecyloxypropyl-cyclic-cidofovir in guinea pigs. J. Ocul. Pharmacol. Ther. 21(3):205-209, 2005.
24. Akler, M.E., Johnson, D.W., Burman, W.J., et al. Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology 105(4):651-657, 1998.
25. Taskintuna, I., Banker, A.S., Rao, N.A., et al. An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects. Exp. Eye Res. 64(5):795-806, 1997.
26. Banker, A.S., De Clercq, E., Taskintuna, I., et al. Influence of intravitreal injections of HPMPC and related nucleoside analogues on intraocular pressure in guinea pig eyes. Invest. Ophthalmol. Vis. Sci. 39(7):1233-1242, 1998.
27. Rosenberg et al. Acyclic nucleotide analogs. Part II. Synthesis of potential prodrugs and metabolites of 9-(S)-(3-hydroxy-2- phosphonylmethoxypropyl)adenine. Collection Czechoslovak Chem. Comm. 52(11):2792-2800, 1987.
28. Kini, G.D., Beadle, J.R., Xie, H., et al. Alkoxy propane prodrugs of foscarnet: Effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1, and HCMV. Antivir. Res. 36(1):43-53, 1997.
29. Beadle, J.R., Wan, W.B., Ciesla, S.L., et al. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2- phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J. Med. Chem. 49(6):2010-2015, 2006.
30. Cheng, L., Hostetler, K.Y., Gardner, M.F., et al. Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug. Invest. Ophthalmol. Vis. Sci. 40(7):1487-1495, 1999.
31. Nussenblatt, R.B., Palestine, A.G., Chan, C.C., et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92(4):467-471, 1985.
32. Jabs, D.A., Nussenblatt, R.B., and Rosenbaum, J.T. Standardization of uveitis nomenclature for reporting clinical data: Results of the First International Workshop. Am. J. Ophthalmol. 140(3):509-516, 2005.
33. Goldberg, D.E., Smithen, L.M., Angelilli, A., et al. HIV-associated retinopathy in the HAART era. Retina 25(5):633-649; quiz, 682-633, 2005.
34. Wiegand, T.W., and Young, L.H. Cytomegalovirus retinitis. Int. Ophthalmol. Clin. 46(2):91-110, 2006.
35. Cheng, L., Hostetler, K.Y., Toyoguchi, M., et al. Ganciclovir release rates in vitreous from different formulations of 1-O-hexadecylpropanediol-3- phospho-ganciclovir. J. Ocul. Pharmacol. Ther. 19(2):161-169, 2003.
36. Wan, W.B., Beadle, J.R., Hartline, C., et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 49(2):656-662, 2005.